copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Actelion Pharmaceuticals Ltd. – Swiss Biotech Headquartered in Allschwil, Actelion is part of the Johnson Johnson Family of Companies Its ground-breaking research and medicines have been a key contributor to improve the lives of people affected by pulmonary hypertension, and made Actelion an industry leader in this area
J J could pay $17 billion for Actelion - pharmaphorum Johnson Johnson and Switzerland’s specialist pharma company Actelion have confirmed that they are in talks over a possible takeover Both companies confirmed in brief statements that press
New PAH Drug from Actelion Approved by FDA – Pulmonary. . . According to a recent announcement, the United States Food and Drug Administration (FDA) approved Actelion Pharmaceuticals’ Uptravi (selexipag) tablets for the treatment of adult patients with pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization, under orphan drug designation
J J’s $30-Billion Buy of Actelion: What Does It Mean for J J? J J completed its previously announced acquisition of Actelion, a Swiss pharmaceutical company specializing in products for treating pulmonary arterial hypertension, for a total purchase price of approximately $30 billion
Actelion Pharmaceuticals 2025 Company Profile: Valuation, Investors . . . Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration
Actelion Story - Profile, History, Founder, CEO - SuccessStory Actelion Pharmaceuticals Ltd specializes in the invention of medicines for orphan diseases The company is a leader in the field of science and medicine for pulmonary arterial hypertension Innovation is their keyword and the company relies heavily on in-house discovery, development, and marketing